Merck & Co., Inc. news

   Watch this stock
Showing stories 1 - 10 of about 153   

Articles published

MRK 59.58 +0.60 (1.02%)
price chart
Merck to take on superbugs with Cubist Pharma buy
(Reuters) - Merck & Co Inc (MRK.N) said it would buy Cubist Pharmaceuticals Inc (CBST.O) for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.
In $9.5b deal, giant Merck buying Lexington's Cubist  Boston Globe
Merck Said to Weigh Acquisition of Rival Drug Maker Cubist  New York Times
Related articles »  
Merck & Co. (MRK) Seeks $8 Billion Bridge Loan To Acquire Cubist ...
Merck, the second-largest US pharmaceutical player behind Pfizer Inc. (NYSE:PFE), has chosen to stick to its decision to acquire Cubist, possibly because Cubist could have likely slapped the company with a lawsuit if Merck had got cold feet upon the ...
TRLPC: Merck looks for $8B bridge for Cubist acquisition  Reuters
Merck looks for US$8bn bridge for Cubist acquisition  IFR Asia
Related articles »  
5 Things Merck & Co., Inc.'s Management Wants You to Know
It's been about a month since pharmaceutical giant Merck (NYSE: MRK ) reported its third-quarter results, but time hasn't changed the fact that Merck's been struggling mightily with patent expirations and increased competition for its key drugs.
Stock in Focus: Merck & Co., Inc. (NYSE:MRK) Looks to Growth  Markets Wired
Related articles »  
Cubist soars on Merck's $8.4b purchase
Merck & Co. Inc. said last week it will proceed with its planned $8.4 billion purchase of Lexington's Cubist Pharmaceuticals Inc. and still expects the deal to boost its long-term earnings, despite a court ruling that could speed the arrival of generic ...
Related articles »  
Merck & Co. Inc. (MRK) Closes 1.02% Up on the Day for December 19
Merck & Co. Inc. currently has a total float of 2.85 billion shares and moves 10.14 million a day, on average. The stock opened at $59.25 on December 19 and traded between a low of $59.01 and a high of $59.90.
Related articles »  
Zymeworks Inc. and Merck & Co., Inc. Extend and Expand Bi-specific Antibody ...
VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. today announced the extension of a research collaboration with Merck, known as MSD outside the United States and Canada, that was originally announced in August 2011. In addition ...
Related articles »  
Interesting June 2015 Stock Options for Merck & Co.
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Merck & Co., Inc (NYSE: MRK). So this week we highlight one interesting put contract, and one interesting call contract, from the ...
Related articles »  
Merck & Co., Inc. (NYSE:MRK) Acquires OncoEthix
[The Fly] Merck & Co., Inc. (NYSE:MRK) announced that it has acquired, through a subsidiary, OncoEthix, a Swiss-based privately held biotechnology company specializing in oncology drug development.
Nike Inc, Johnson Controls Inc, Merck & Co., Inc., PulteGroup, Inc., Stocks ...
The big news for Merck is that it's paying $8.4 billion to buy Cubist Pharmaceuticals (NASDAQ: CBST). The big benefit of the deal is that it gives Merck a stronger presence in hospitals and antibiotics - a couple fast-growing areas of the pharma ...
Merck buys Swiss biotech firm (MRK)
Merck (NYSE:MRK) acquires privately-held Lausanne, Switzerland-based Oncoethix for an upfront payment of $110M and up to an additional $265M in clinical and regulatory milestones.